It is very uncertain whether direct‐acting antivirals changes all‐cause mortality at maximum compared with control (very low certainty).
It is very uncertain whether direct‐acting antivirals changes proportion of participants with one or more serious adverse event at… compared with control (very low certainty).
Direct‐acting antivirals may leads to lower proportion of participants with no sustained virological response at… compared with control (low certainty).
It is very uncertain whether direct‐acting antivirals withdrawn from the market changes all‐cause mortality at maximum compared with control (very low certainty).
It is very uncertain whether direct‐acting antivirals withdrawn from the market changes proportion of participants with one or more serious adverse event at… compared with control (very low certainty).
Direct‐acting antivirals withdrawn from the market may leads to lower proportion of participants with no sustained virological response at… compared with control (low certainty).
It is very uncertain whether tenofovir‐based antiviral combination regimens changes all‐cause infant mortality at longest compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).
It is very uncertain whether tenofovir‐based antiviral combination regimens changes proportion of infants with serious adverse events ( compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).
It is very uncertain whether tenofovir‐based antiviral combination regimens changes proportion of mothers with serious adverse events ( compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).